InChI=1S/C19H21NO4/c1- 2- 8- 20- 9- 7- 18- 15- 11- 3- 4- 12(21) 16(15) 24- 17(18) 13(22) 5- 6- 19(18,23) 14(20) 10- 11/h2- 4,14,17,21,23H,1,5- 10H2/t14- ,17+,18+,19- /m1/s1 |
UZHSEJADLWPNLE-GRGSLBFTSA-N |
Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C |
|
mu-opioid receptor antagonist
Any compound that exhibits antagonist activity at the mu-opioid receptor
metabolite
Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
(via alkaloid )
|
|
mu-opioid receptor antagonist
Any compound that exhibits antagonist activity at the mu-opioid receptor
central nervous system depressant
A loosely defined group of drugs that tend to reduce the activity of the central nervous system.
antidote to opioid poisoning
A role borne by a molecule that acts to counteract or neutralise the deleterious effects of opioids.
|
|
View more via ChEBI Ontology
3,14-dihydroxy-17-(prop-2-en-1-yl)-4,5α-epoxymorphinan-6-one
|
naloxona
|
DrugBank
|
naloxone
|
WHO MedNet
|
naloxone
|
ChemIDplus
|
naloxonum
|
DrugBank
|
(−)-naloxone
|
ChEBI
|
1-N-Allyl-14-hydroxynordihydromorphinone
|
ChemIDplus
|
17-allyl-3,14-dihydroxy-4,5α-epoxymorphinan-6-one
|
ChEBI
|
1089071
|
Reaxys Registry Number
|
Reaxys
|
465-65-6
|
CAS Registry Number
|
KEGG COMPOUND
|
465-65-6
|
CAS Registry Number
|
ChemIDplus
|
465-65-6
|
CAS Registry Number
|
NIST Chemistry WebBook
|
17023477
|
PubMed citation
|
Europe PMC
|
24868924
|
PubMed citation
|
Europe PMC
|
25468814
|
PubMed citation
|
Europe PMC
|
26469689
|
PubMed citation
|
Europe PMC
|
26604818
|
PubMed citation
|
Europe PMC
|
26634308
|
PubMed citation
|
Europe PMC
|
|